Athanasios Papadopoulos, a former Sanofi SA executive, has joined Emergex Vaccines Holding Ltd as chief medical officer. Based in Oxford, UK, Emergex is working on a new approach to synthetic vaccine development. Dr Papadopoulos will oversee the company’s preclinical portfolio. Dr Papadopoulos joins Emergex from Sanofi where he played a role in the development of the company’s Dengue fever vaccine. Prior to this, he was medical affairs director at Novartis where he contributed to the development of the meningitis B vaccine, Bexsero. Dr Papadopoulos trained as a general practitioner in Greece and specialised as a clinical biopathology consultant.
Emergex Vaccines announced the appointment on 27 February 2019.
Copyright 2019 Evernow Publishing Ltd